Johnson & Johnson Innovative Medicine

#PHridayPHacts: #PulmonaryHypertension (PH) most often affects people between the ages of 30 and 60. It often takes patients years to receive a proper diagnosis, which can delay care and worsen outcomes. As we age, the risk of developing Group 1 PH, known as #PulmonaryArterialHypertension (PAH), increases. #JNJCardiopulmonary

In muscle-invasive #BladderCancer, some patients undergo surgery without the benefit of pre-surgical therapy, a factor that can negatively affect outcomes. At Johnson & Johnson, we’re reimagining drug delivery and exploring new approaches. The latest data presented at #ESMO25 provide important insights that may help inform future treatments for patients. Learn how we’re working to advance care for patients facing this aggressive, life-altering disease : https://lnkd.in/ebtPaK3Y #JNJOncology

Over the last 15 years, oncology has seen remarkable breakthroughs—immunotherapy, CAR T-cell therapies, the advent of precision medicine, DNA sequencing, liquid biopsies and new tools to screen for cancers. But with rapid innovation, comes new challenges. As oncology strategist Alyssa Hulahan-Castellano shared, many clinicians are feeling the pressure of nonstop change. Our Oncology Care Index confirms these struggles. 75% of oncologists find the pace of new treatment development overwhelming, while 70% struggle to navigate the complexities of cancer treatment guidelines. To keep innovation moving forward, oncologists see opportunities in collaboration, AI and broader clinical trial access. Explore more insights from the Oncology Care Index: https://lnkd.in/eyshABXA #JNJOncology #InFrontOfCancer

Rare autoantibody diseases like warm autoimmune hemolytic anemia (wAIHA) place a heavy mental and emotional toll on patients. New research presented at the 2025 #NORDSummit highlights the critical impact of partnering with patients to guide the development of educational resources. At Johnson & Johnson we believe progress is only possible through true partnership and collaboration with patients. Join us as we continue to reimagine rare autoantibody disease research and help shape solutions that can transform care and improve lives for patients everywhere. Learn more about the unmet need in wAIHA: https://bit.ly/3WF0Qou #JNJImmunology

Progress in cancer care is built one discovery at a time. That’s why we’re delivering bold advancements in solid tumor treatment to address some of the most urgent unmet needs for patients worldwide. Our data at the 2025 ESMO - European Society for Medical Oncology Congress showcase the depth of our pipeline and the promise of our innovation. Across lung, bladder, prostate, and head and neck cancer, we’re driving the next wave of transformative therapies for patients: https://bit.ly/4qdr7I4 #JNJOncology #ESMO25

As a company driven by innovation, Johnson & Johnson is actively exploring emerging Artificial Intelligence and Machine Learning (AI/ML) techniques to help advance drug discovery and development. To build on this commitment, we are proud to announce the launch of the Pitching Critical Assessment for Therapeutic Protein Design (CAT-PD) QuickFire Challenge. Innovators worldwide are invited to submit their potentially transformative computational techniques aimed at designing antibody sequences de novo against “hard-to-drug” targets. Apply by November 21 for the opportunity to showcase your models/technologies to Johnson & Johnson Innovative Medicine R&D leadership. https://bit.ly/3W88Myv

Our bispecific antibody research began with a clear mission: to deliver new treatment options to patients in need. That mission guided every step—from early discovery to clinical development—and through collaboration, it became a reality. Watch our panel discussion on how we’re driven by the urgency to help patients with the fewest options— learning from our experiences to set the stage for future innovation in oncology research. https://bit.ly/43dz1aB #JNJOncology

Superheroes? Without a doubt. This American Pharmacists Month and every month, pharmacists are part of “The Indispensables.” Today’s superhero is: The Specialist! For patients facing complex conditions like cancer, rare diseases, or autoimmune disorders, navigating and understanding treatment can be challenging. The Specialist helps patients feel confident throughout their treatment program. They provide counsel on the use and side effects of medications, and monitor progress to help patients stay on therapy longer, with the goal of achieving the best possible health outcomes. Join us in celebrating their work by tagging a pharmacist who is a Specialist! #AmericanPharmacistsMonth #Indispensable #APhM2025 #CaringForOurCommunities

At Johnson & Johnson Innovative Medicine, our Global Development U.S. Internship Program offers hands-on experience in clinical research, data science, and business operations, all focused on bringing life-changing medicines to patients faster. The 2026 summer program is open to U.S.-based undergraduate students and blends real-world experience with mentoring, networking, and professional development, empowering you to make an impact from day one. Take the first step toward transforming the future of healthcare — apply today! https://lnkd.in/gqnVekNX #JNJ #GlobalDevelopment #Innovation #Internship #Healthcare #EarlyTalent #ClinicalResearch

Advances in science help us better understand thrombosis, or the formation of blood clots that can lead to frequent cardiovascular events, including heart attacks, strokes and pulmonary embolisms. Factor XIa (FXIa) is a potential key therapeutic target that may lower clotting risk while reducing potential bleeding risks. This World Thrombosis Day, we’re collaborating with Bristol Myers Squibb to advance research on FXIa. Together, we’re working to develop innovative treatment options that could improve prevention and outcomes for people living with thrombotic conditions. Learn more about FXIa, the science behind it and how this partnership is driving progress in cardiovascular care: https://bit.ly/4h8TvXH #WTDay25